Lumonus, a healthcare technology company focused on AI-driven radiation oncology workflows, announced a strategic collaboration with Memorial Sloan Kettering Cancer Center to advance automated radiation therapy treatment planning.
Through the partnership, Lumonus will license and co-develop MSK’s ECHO mathematical optimization engine within its platform, while also investing in joint research to enhance automation capabilities in radiation oncology. The collaboration aims to address long-standing challenges in scaling automated treatment planning, particularly the need to balance complex, patient-specific clinical constraints while consistently delivering optimal treatment plans.
ECHO, developed at MSK over nearly a decade, uses constraint-based mathematical optimization to generate radiation therapy plans from first principles. The system has been validated through extensive clinical use and peer-reviewed research, positioning it as one of the most rigorously tested approaches in the field.
Lumonus said the integration of ECHO into its AI platform, combined with advanced workflow tools, is intended to improve treatment quality, consistency, and efficiency while reducing administrative burden. The companies aim to accelerate the transition of automated planning from experimental use cases to routine clinical deployment.
The Lumonus AI platform is designed to automate and orchestrate critical oncology tasks, supporting clinicians with AI-native workflows. The company operates across the United States, Australia, and Europe.
KEY QUOTES
“Over the last twenty years, automated planning systems have demonstrated real clinical value — improving dosimetric quality, consistency and efficiency across multiple studies. But scaled adoption has remained elusive. The core challenge is that each plan must navigate complex, competing constraints that are specific to the individual patient, and there has been no robust way to consistently produce the optimal solution and confirm it meets the treating physician’s clinical intent,”
“Our strategic collaboration with MSK represents a decisive step forward. The next generation of planning automation requires a mathematically principled solver capable of consistently delivering the optimal plan, working in concert with intelligent review tools that capture the nuanced clinical judgement of physicians in real-world practice. Together with MSK, we are building the infrastructure to move automation from promising results to scaled, routine deployment.”
Tim Fox, Chief Product Officer, Lumonus
“Our goal in developing ECHO has always been to improve the quality, consistency, and efficiency of radiation therapy treatment planning,”
“Our collaboration with Lumonus creates an important opportunity to combine clinically validated optimization methods with modern workflow tools and help expand the adoption of automated treatment planning in radiation oncology.”
Masoud Zarepisheh, PhD, Associate Attending And Lead Developer Of ECHO, Memorial Sloan Kettering Cancer Center
